Asad Umar

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Chemoprevention of colorectal carcinogenesis
    Asad Umar
    Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, EPN, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Int J Clin Oncol 7:2-26. 2002
  2. ncbi request reprint The role of cyclooxygenase inhibitors in cancer prevention
    William F Anderson
    Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, EPN, Room 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Curr Pharm Des 8:1035-62. 2002
  3. ncbi request reprint Applications of bioinformatics in cancer detection: a lexicon of bioinformatics terms
    Asad Umar
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Ann N Y Acad Sci 1020:263-76. 2004
  4. doi request reprint Future directions in cancer prevention
    Asad Umar
    National Cancer Institute, Division of Cancer Prevention, Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Executive Plaza North 2142, 6130 Executive Boulevard, MSC 7317, Rockville, Maryland 20852 7371, USA
    Nat Rev Cancer 12:835-48. 2012
  5. ncbi request reprint Testing guidelines for hereditary non-polyposis colorectal cancer
    Asad Umar
    Division of Cancer Prevention and Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Cancer 4:153-8. 2004
  6. pmc Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability
    Asad Umar
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    J Natl Cancer Inst 96:261-8. 2004
  7. ncbi request reprint Lynch syndrome (HNPCC) and microsatellite instability analysis guidelines
    Asad Umar
    Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Blvd, Rockville, MD 20852, USA
    Cancer Biomark 2:1-4. 2006
  8. ncbi request reprint Development of COX inhibitors in cancer prevention and therapy
    Asad Umar
    Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, Bethesda, Maryland 20892 7317, USA
    Am J Clin Oncol 26:S48-57. 2003
  9. ncbi request reprint Gene expression analysis of tumor infiltrating lymphocyte markers in endometrial cancers indicates no significant increases in those cases with microsatellite instability
    John I Risinger
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Cancer Biomark 2:61-8. 2006
  10. ncbi request reprint Non-steroidal anti-inflammatory and cyclooxygenase-2-selective inhibitors in clinical cancer prevention trials
    Ernest T Hawk
    Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, Bethesda, MD, USA
    Prog Exp Tumor Res 37:210-42. 2003

Detail Information

Publications31

  1. ncbi request reprint Chemoprevention of colorectal carcinogenesis
    Asad Umar
    Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, EPN, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Int J Clin Oncol 7:2-26. 2002
    ..These targets will help identify more effective and better tolerated preventive agents. Carcinogenesis is now recognized as a disease in itself and has become the target of an ever-expanding array of preventive interventions...
  2. ncbi request reprint The role of cyclooxygenase inhibitors in cancer prevention
    William F Anderson
    Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, EPN, Room 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Curr Pharm Des 8:1035-62. 2002
    ..Nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase (COX) -1 and -2 are among the most promising classes of agents for targeted molecular prevention...
  3. ncbi request reprint Applications of bioinformatics in cancer detection: a lexicon of bioinformatics terms
    Asad Umar
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Ann N Y Acad Sci 1020:263-76. 2004
    ..This paper compiles a list of numerous bioinformatics terms for the Applications of Bioinformatics in Cancer Detection conference. It should be helpful as a lexicon for the volume as a whole...
  4. doi request reprint Future directions in cancer prevention
    Asad Umar
    National Cancer Institute, Division of Cancer Prevention, Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Executive Plaza North 2142, 6130 Executive Boulevard, MSC 7317, Rockville, Maryland 20852 7371, USA
    Nat Rev Cancer 12:835-48. 2012
    ....
  5. ncbi request reprint Testing guidelines for hereditary non-polyposis colorectal cancer
    Asad Umar
    Division of Cancer Prevention and Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Cancer 4:153-8. 2004
  6. pmc Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability
    Asad Umar
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    J Natl Cancer Inst 96:261-8. 2004
    ....
  7. ncbi request reprint Lynch syndrome (HNPCC) and microsatellite instability analysis guidelines
    Asad Umar
    Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Blvd, Rockville, MD 20852, USA
    Cancer Biomark 2:1-4. 2006
  8. ncbi request reprint Development of COX inhibitors in cancer prevention and therapy
    Asad Umar
    Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, Bethesda, Maryland 20892 7317, USA
    Am J Clin Oncol 26:S48-57. 2003
    ..Discovering how to apply NSAIDs in persons with-or at risk for-cancer, although challenging, has the potential for considerable clinical and public health benefits...
  9. ncbi request reprint Gene expression analysis of tumor infiltrating lymphocyte markers in endometrial cancers indicates no significant increases in those cases with microsatellite instability
    John I Risinger
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Cancer Biomark 2:61-8. 2006
    ..These data indicate that significant differences in TIL derived transcripts do not occur between endometrioid endometrial cancers with and without microsatellite instability...
  10. ncbi request reprint Non-steroidal anti-inflammatory and cyclooxygenase-2-selective inhibitors in clinical cancer prevention trials
    Ernest T Hawk
    Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, Bethesda, MD, USA
    Prog Exp Tumor Res 37:210-42. 2003
  11. ncbi request reprint Cyclooxygenase inhibition in cancer prevention and treatment
    William F Anderson
    Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, EPN, Room 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Expert Opin Pharmacother 4:2193-204. 2003
    ..A brief discussion on the pharmacoeconomic considerations of NSAID and COXIB use and safety issues that have recently been the focus of debate, will be presented...
  12. ncbi request reprint Colorectal cancer chemoprevention--an overview of the science
    Ernest T Hawk
    Gastrointentinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute NIH, EPN Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Gastroenterology 126:1423-47. 2004
    ..Innovative research models include the nesting of prevention end points within cancer treatment trials and within trials testing promising preventive compounds intended for nononcologic indications...
  13. ncbi request reprint Non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention
    Ernest T Hawk
    National Cancer Institute, Division of Cancer Prevention, Bethesda, MD 20892 7317, USA
    Cancer Chemother Biol Response Modif 21:759-89. 2003
  14. ncbi request reprint Early detection and risk assessment: proceedings and recommendations from the Workshop on Epigenetics in Cancer Prevention
    Mukesh Verma
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20852, USA
    Ann N Y Acad Sci 983:298-319. 2003
    ..Further research will lead to the identification of new targets for cancer prevention...
  15. ncbi request reprint Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signaling
    John I Risinger
    Laboratory of Biosystems and Cancer, National Cancer Institute, Bethesda, Maryland, USA
    Cancer Res 65:5031-7. 2005
    ..These data classify histologically similar endometrioid endometrial cancers into two distinct groupings with implications affecting therapy and prevention...
  16. ncbi request reprint Chemoprevention of colorectal cancer: problems, progress, and prospects
    Jaye L Viner
    Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, EPN, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Gastroenterol Clin North Am 31:971-99. 2002
    ..The number of trials that are investigating chemopreventives against CR neoplasia is relatively small; if these agents live up to a fraction of their promise, the public health impact may be great (see Table 6)...
  17. ncbi request reprint Can animal models help us select specific compounds for cancer prevention trials?
    Ernest T Hawk
    GI and Other Cancers Research Group, National Cancer Institute, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Recent Results Cancer Res 166:71-87. 2005
    ....
  18. ncbi request reprint Lynch syndrome (HNPCC) and microsatellite instability
    Asad Umar
    Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, EPN, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Dis Markers 20:179-80. 2004
  19. ncbi request reprint Prevention and therapy of colorectal cancer
    Ernest T Hawk
    Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, EPN, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Med Clin North Am 89:85-110, viii. 2005
    ..These advances substantiate target-driven approaches to cancer prevention and treatment, and provide fruitful opportunities for future investigations...
  20. pmc One year recurrence of aberrant crypt foci
    Paul F Pinsky
    Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892, USA
    Cancer Prev Res (Phila) 3:839-43. 2010
    ..After removal of ACF at baseline, ACF counts 1 year later were only slightly reduced and were significantly correlated with the baseline ACF count. The results of this study do not support a role for ACF in clinical practice...
  21. ncbi request reprint Epigenetics in cancer prevention: early detection and risk assessment: introduction
    Barbara K Dunn
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Executive Plaza North, Rockville, Maryland 20852 7362, USA
    Ann N Y Acad Sci 983:1-4. 2003
  22. ncbi request reprint The promise of biomarkers in colorectal cancer detection
    Asad Umar
    Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, 6130 Executive Blvd EPN 2143, Rockville, MD 20852, USA
    Dis Markers 20:87-96. 2004
  23. doi request reprint Further thoughts on preclinical animal models for cancer prevention: when is it best to start treatment? What are potential histopathologic endpoints?
    Asad Umar
    Division of Cancer Prevention, Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Bethesda, MD, USA
    Semin Oncol 37:339-44. 2010
    ....
  24. ncbi request reprint DNA methylation as a cancer-specific biomarker: from molecules to populations
    Arti Patel
    Cancer Prevention Fellowship Program, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892, USA
    Ann N Y Acad Sci 983:286-97. 2003
    ....
  25. ncbi request reprint Proceedings: the Applications of Bioinformatics in Cancer Detection Workshop
    Izet M Kapetanovic
    Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 7322, USA
    Ann N Y Acad Sci 1020:1-9. 2004
    ..This paper summarizes the proceedings of this conference and points out future directions for research...
  26. ncbi request reprint Colorectal carcinoma in black and white race
    William F Anderson
    National Cancer Institute Division of Cancer Prevention Gastrointestinal Cancer and Other Cancers Research Group, Bethesda, Maryland, USA
    Cancer Metastasis Rev 22:67-82. 2003
    ..Racial variations demonstrate the need for a more comprehensive understanding of colorectal carcinogenesis, epidemiology, and colorectal screening patterns for low- and high-risk populations...
  27. ncbi request reprint Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-alpha gene in rat colon tumors
    Michael A Pereira
    Department of Pathology, Medical College of Ohio, Toledo, OH 43614, USA
    Carcinogenesis 25:1917-23. 2004
    ..Celecoxib and DFMO reversed DNA hypomethylation and the hypermethylation of the ER-alpha gene in colon tumors supporting the hypothesis that modulation of methylation is a biomarker of chemoprevention...
  28. ncbi request reprint Serum proteomic profiles suggest celecoxib-modulated targets and response predictors
    Zhen Xiao
    Laboratory of Proteomics and Analytical Technologies and Advanced Biomedical Computing Center, SAIC Frederick Inc, National Cancer Institute at Frederick, Frederick, Maryland, USA
    Cancer Res 64:2904-9. 2004
    ..In particular, a spectral feature at m/z 16,961.4 was identified as a strong discriminator between response and nonresponse to celecoxib at the highest dose...
  29. ncbi request reprint An Msh2 point mutation uncouples DNA mismatch repair and apoptosis
    Diana P Lin
    Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York, USA
    Cancer Res 64:517-22. 2004
    ....
  30. doi request reprint The natural history of aberrant crypt foci
    Robert E Schoen
    University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Gastrointest Endosc 67:1097-102. 2008
    ..Aberrant crypt foci (ACF) are the putative precursors to colorectal adenomas and may be useful as biomarkers. Knowledge of their natural history is essential to understanding their potential utility...
  31. ncbi request reprint Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors
    Qiang Lu
    Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA
    J Med Chem 47:467-74. 2004
    ....